Mitsubishi Tanabe to buy Israel's NeuroDerm for $1.1 bn

July 24, 2017

Japan's Mitsubishi Tanabe Pharma announced Monday a billion-dollar deal to buy an Israeli company that specialises in developing treatments for Parkinson's disease.

The Osaka-based firm said it will acquire all of Nasdaq-listed NeuroDerm's outstanding shares for $1.1 billion at a price of $39 per share.

The deal is subject to approval by NeuroDerm shareholders as well as regulatory approval.

NeuroDerm develops treatments for patients suffering from Parkinson's disease, as well as other disorders related to the central nervous system.

The company, which has been supported by grants from the Michael J Fox Foundation for Parkinson's Research, aims to radically change the way the disease is treated through reformulating existing drugs.

Its current lead product candidate is in advanced in Europe and the United States and could hit the market as early as 2019, Mitsubishi Tanabe said.

Explore further: Elan enters $1B royalty deal with Theravance

Related Stories

Elan enters $1B royalty deal with Theravance

May 13, 2013
Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Scientific discovery may change treatment of Parkinson's disease

March 22, 2017
When monitoring Parkinson's disease, SPECT imaging of the brain is used for acquiring information on the dopamine activity. A new study conducted in Turku, Finland, shows that the dopamine activity observed in SPECT imaging ...

Horizon Pharma to pay $800M for rare disease drug developer

September 12, 2016
Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

Adamas Pharma rises after IPO raises $48 million

April 10, 2014
Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

AmerisourceBergen expands into animal health with $2.5B deal

January 12, 2015
Pharmaceutical distributor AmerisourceBergen will stretch its reach into veterinary medicine by spending about $2.5 billion to acquire MWI Veterinary Supply.

Teva buying Auspex for $3.2 billion

March 30, 2015
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Recommended for you

Genetic defects in the cell's 'waste disposal system' linked to Parkinson's disease

November 14, 2017
An international study has shed new light on the genetic factors associated with Parkinson's disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of ...

Parkinson's disease: A looming pandemic

November 13, 2017
New research shows that the number of people with Parkinson's disease will soon grow to pandemic proportions. In a commentary appearing today in the journal JAMA Neurology, University of Rochester Medical Center neurologist ...

Focused ultrasound shows promise for treating Parkinson's tremor

October 30, 2017
An initial test to determine if a scalpel-free form of brain surgery can reduce tremor caused by Parkinson's disease has produced encouraging results. Further research is warranted, the researchers conclude in a paper published ...

Novel technique explains herbicide's link to Parkinson's disease

October 23, 2017
Northwestern Medicine scientists have used an innovative gene editing technique to identify the genes that may lead to Parkinson's disease after exposure to paraquat, a commonly-used herbicide.

Data, technology drive new approaches to Parkinson's care

October 23, 2017
Complex, multi-system diseases like Parkinson's have long posed challenges to both scientists and physicians. University of Rochester Medical Center (URMC) researchers are now reaching for new tools, such as algorithms, ...

Investigating the most common genetic contributor to Parkinson's disease

October 19, 2017
LRRK2 gene mutations are the most common genetic cause of Parkinson's disease (PD), but the normal physiological role of this gene in the brain remains unclear. In a paper published in Neuron, Brigham and Women's Hospital ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.